Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary Heart Disease Patients from the CORDIOPREV Study

Circulating microRNAs (miRNAs) have been proposed as type 2 diabetes biomarkers, and they may be a more sensitive way to predict development of the disease than the currently used tools. Our aim was to identify whether circulating miRNAs, added to clinical and biochemical markers, yielded better pot...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy. Nucleic acids 2018-09, Vol.12, p.146-157
Main Authors: Jiménez-Lucena, Rosa, Rangel-Zúñiga, Oriol Alberto, Alcalá-Díaz, Juan Francisco, López-Moreno, Javier, Roncero-Ramos, Irene, Molina-Abril, Helena, Yubero-Serrano, Elena Maria, Caballero-Villarraso, Javier, Delgado-Lista, Javier, Castaño, Justo Pastor, Ordovás, Jose Maria, Pérez-Martinez, Pablo, Camargo, Antonio, López-Miranda, José
Format: Article
Language:English
Subjects:
Biochemical markers
Biomarkers
Cardiovascular disease
Coronary artery disease
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Discriminant analysis
Gene expression
Glucose
Heart diseases
Hemoglobin
Homeostasis
Insulin resistance
MicroRNAs
miRNA
miRNAs
Plasma levels
predictive models
Risk assessment
Studies
type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating microRNAs (miRNAs) have been proposed as type 2 diabetes biomarkers, and they may be a more sensitive way to predict development of the disease than the currently used tools. Our aim was to identify whether circulating miRNAs, added to clinical and biochemical markers, yielded better potential for predicting type 2 diabetes. The study included 462 non-diabetic patients at baseline in the CORDIOPREV study. After a median follow-up of 60 months, 107 of them developed type 2 diabetes. Plasma levels of 24 miRNAs were measured at baseline by qRT-PCR, and other strong biomarkers to predict diabetes were determined. The ROC analysis identified 9 miRNAs, which, added to HbA1c, have a greater predictive value in early diagnosis of type 2 diabetes (AUC = 0.8342) than HbA1c alone (AUC = 0.6950). The miRNA and HbA1c-based model did not improve when the FINDRISC was included (AUC = 0.8293). Cox regression analyses showed that patients with low miR-103, miR-28-3p, miR-29a, and miR-9 and high miR-30a-5p and miR-150 circulating levels have a higher risk of disease (HR = 11.27; 95% CI = 2.61–48.65). Our results suggest that circulating miRNAs could potentially be used as a new tool for predicting the development of type 2 diabetes in clinical practice.
ISSN:2162-2531
2162-2531
DOI:10.1016/j.omtn.2018.05.002